Vol. 6, Issue 3 (2017)
To study the adequacy of myocardial protection with cardioplegia solution in patients undergoing cardiac surgery using CPK-MB as biomarker
Dr. Mathew George, Dr. Lincy Joseph, Rani Manju, Gifty Ann Thomas, Maleetha Shamsudeen, Shefali K Thomas and Vineetha CJ
The use of cardioplegia (pharmacologically induced electromechanical arrest) to achieve the ideal conditions for cardiac surgical operations was introduced over 20 years ago in clinical practice. The goals of myocardial protection during cardiac surgery are not only to facilitate the operation by providing a bloodless field, thereby facilitating the precision of the operation, but also to avoid iatrogenic injury induced by cardiopulmonary bypass itself or by surgically impose ischemia. Cardioplegia plays a very important role in myocardial protection strategies. Acting as perfusion agent, cardioplegia solutions can alter or inhibit ischemic injury by virtue of hypothermia and asystole. In addition, cardioplegia solutions can be used to avoid reperfusion injury. CPK-MB is the most sensitive and the most specific indicator available for the diagnosis of an acute myocardial infarction. This review is designed to investigate the adequacy of cardioplegia solution in coronary artery bypass grafting and its role in protecting the myocardium.
Method: This is a prospective analytical study is going to be conducted in the department of Cardiothoracic and Vascular Surgery, Pushpagiri Medical College Hospital, Thiruvalla. All patients who is willing to participate in the study is briefly explained about the study procedure. Approximately 60-65 patients will be taken into consideration. Blood sample (residual) of 3ml is required which is obtained from the laboratory and CPK-MB level is estimated 6th and 12th hourly after administration of cardioplegic solution. The patients are selected based on inclusion and exclusion criteria. The level of biomarker can be analysed by using semi auto analyzer. The results obtained from the study can be compared with the normal range of CPK MB in blood. Follow up will be conducted during the study period.
How to cite this article:
Dr. Mathew George, Dr. Lincy Joseph, Rani Manju, Gifty Ann Thomas, Maleetha Shamsudeen, Shefali K Thomas and Vineetha CJ. . The Pharma Innovation Journal. 2017; 6(3): 90-93.